2017
Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes
Tamborlane WV, Laffel LM, Weill J, Gordat M, Neubacher D, Retlich S, Hettema W, Hoesl CE, Kaspers S, Marquard J. Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 640-648. PMID: 29171139, DOI: 10.1111/pedi.12616.Peer-Reviewed Original ResearchConceptsDPP-4 inhibitionDipeptidyl peptidase-4 inhibitor linagliptinType 2 diabetesInhibitor linagliptinAdult patientsPediatric patientsPlacebo-controlled dose-finding studyDrug-related adverse eventsPrimary efficacy endpointParallel-group studyWeeks of treatmentDose-finding studyDose-dependent reductionEfficacy endpointMean HbA1cAdverse eventsFPG levelsTrough levelsClinical efficacySafety profilePlasma glucosePharmacodynamic endpointsStudy populationPatientsLinagliptinAltered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrate
2016
Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL. Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology & Therapeutics 2016, 18: 794-799. PMID: 27996320, PMCID: PMC5178000, DOI: 10.1089/dia.2016.0311.Peer-Reviewed Original ResearchConceptsClosed-loop insulin deliveryPlasma glucoseEnd of exercisePG levelsExercise studiesInsulin deliveryExercise periodCL insulin deliveryExercise-induced loweringType 1 diabetes subjectsExercise-induced reductionRecovery periodBrisk treadmillDL increaseRescue treatmentDiabetes subjectsInsulin infusionExerciseInsulinSimilar differencesVisitsCL controlDeliveryGlucosePeriodGlucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2015
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2015, 39: 264-270. PMID: 26681725, PMCID: PMC4722945, DOI: 10.2337/dc15-1498.Peer-Reviewed Original ResearchConceptsInsulin-induced hypoglycemiaType 1 diabetesIntramuscular glucagonIntranasal glucagonSevere hypoglycemiaPlasma glucoseCrossover noninferiority trialTreatment of hypoglycemiaLoss of consciousnessReal-world managementDosing visitsGlucagon responseIntravenous insulinNoninferiority studyGlucagon administrationClinical centersFacial discomfortNoninferiority trialHospital settingGlucagon preparationHypoglycemiaTherapeutic insulinGlucagonType 1Mean time
2006
The Effects of Aerobic Exercise on Glucose and Counterregulatory Hormone Concentrations in Children With Type 1 Diabetes
Tansey MJ, Tsalikian E, Beck RW, Mauras N, Buckingham BA, Weinzimer SA, Janz KF, Kollman C, Xing D, Ruedy KJ, Steffes MW, Borland TM, Singh RJ, Tamborlane WV. The Effects of Aerobic Exercise on Glucose and Counterregulatory Hormone Concentrations in Children With Type 1 Diabetes. Diabetes Care 2006, 29: 20-25. PMID: 16373890, PMCID: PMC2396943, DOI: 10.2337/diacare.29.01.06.dc05-1192.Peer-Reviewed Original ResearchConceptsType 1 diabetesOral glucoseNorepinephrine concentrationsAerobic exerciseExercise sessionsGrowth hormoneAcute glucose-lowering effectGlucose concentrationAerobic exercise resultsLow glucoseIncidence of hypoglycemiaExercise-induced increaseGlucose-lowering effectCounterregulatory hormone concentrationsTarget heart rateTreatment of hypoglycemiaPlasma glucose concentrationDl risePlasma glucagonPlasma glucoseBlood glucoseVs. 6Baseline glucoseBaseline valuesHeart rate
2004
The Normal Glucose Tolerance Continuum in Obese Youth: Evidence for Impairment in β-Cell Function Independent of Insulin Resistance
Yeckel CW, Taksali SE, Dziura J, Weiss R, Burgert TS, Sherwin RS, Tamborlane WV, Caprio S. The Normal Glucose Tolerance Continuum in Obese Youth: Evidence for Impairment in β-Cell Function Independent of Insulin Resistance. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 747-754. PMID: 15522932, DOI: 10.1210/jc.2004-1258.Peer-Reviewed Original ResearchConceptsBeta-cell responsivenessNormal glucose tolerancePlasma glucose levelsGlucose levelsGlucose toleranceInsulin sensitivityPlasma glucoseObese youthOral glucose tolerance testType 2 diabetes mellitusDecreased insulinogenic indexGlucose tolerance continuumGlucose tolerance testInsulin sensitivity indexContinuum of riskDelta insulinInsulinogenic indexDiabetes mellitusInsulin resistancePlasma levelsTolerance testNormal rangeFunction IndependentDlGlucose concentrationValidation of Insulin Sensitivity Indices from Oral Glucose Tolerance Test Parameters in Obese Children and Adolescents
Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS, Tamborlane WV, Caprio S. Validation of Insulin Sensitivity Indices from Oral Glucose Tolerance Test Parameters in Obese Children and Adolescents. The Journal Of Clinical Endocrinology & Metabolism 2004, 89: 1096-1101. PMID: 15001593, DOI: 10.1210/jc.2003-031503.Peer-Reviewed Original ResearchConceptsWhole-body insulin sensitivity indexOral glucose tolerance testInsulin sensitivity indexIntramyocellular lipid contentInsulin sensitivityInsulin resistanceObese youthLarge cohortComposite whole body insulin sensitivity indexOral glucose tolerance test parametersSurrogate indexClamp-derived insulin sensitivityImpaired glucose toleranceGlucose tolerance testType 2 diabetesEuglycemic hyperinsulinemic clampInsulin sensitivity measurementsGlucose toleranceMetabolic syndromeObese childrenObese populationPoor functionPlasma glucoseTolerance testInsulin response
2003
Defective Activation of Skeletal Muscle and Adipose Tissue Lipolysis in Type 1 Diabetes Mellitus during Hypoglycemia
Enoksson S, Caprio SK, Rife F, Shulman GI, Tamborlane WV, Sherwin RS. Defective Activation of Skeletal Muscle and Adipose Tissue Lipolysis in Type 1 Diabetes Mellitus during Hypoglycemia. The Journal Of Clinical Endocrinology & Metabolism 2003, 88: 1503-1511. PMID: 12679430, DOI: 10.1210/jc.2002-021013.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAdrenergic beta-AgonistsAdultBlood GlucoseDiabetes Mellitus, Type 1EpinephrineFatty Acids, NonesterifiedFemaleGlucoseGlucose Clamp TechniqueGlycerolHomeostasisHumansHypoglycemiaInsulinLactic AcidLipolysisMaleMuscle, SkeletalNorepinephrineReceptors, Adrenergic, beta-2TerbutalineConceptsT1DM patientsControl subjectsGlucose disposalAdipose tissueType 1 diabetes mellitus patientsWhole-body glucose disposalWhole-body glucose useSkeletal muscleDiabetes mellitus patientsGlucagon secretory responsesRisk of hypoglycemiaPlasma epinephrine concentrationSeverity of hypoglycemiaAdipose tissue lipolysisMajor target tissuesHyperinsulinemic euglycemiaAgonist terbutalineAdrenomedullary responseMellitus patientsNondiabetic subjectsDeficient releasePlasma epinephrinePlasma glucoseInsulin infusionCatecholamine secretion
1995
Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children
Jones TW, Borg WP, Boulware SD, McCarthy G, Sherwin RS, Tamborlane WV. Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children. The Journal Of Pediatrics 1995, 126: 171-177. PMID: 7844661, DOI: 10.1016/s0022-3476(95)70541-4.Peer-Reviewed Original ResearchConceptsClinical Research CenterHealthy childrenPlasma glucose concentrationAdrenomedullary responseHypoglycemic clampSymptom scoresSugar ingestionStandard oral glucose loadOral glucose loadPlasma epinephrine levelsPlasma glucose levelsGlucose concentrationCognitive effectsSugar-free drinksP300 potentialEpinephrine levelsP300 auditoryGlucose loadInsulin levelsSymptomatic responsePlasma glucoseOral administrationGlucose levelsHormone concentrationsPhysiologic mechanisms
1993
Effect of caffeine on the recognition of and responses to hypoglycemia in humans.
Kerr D, Sherwin RS, Pavalkis F, Fayad PB, Sikorski L, Rife F, Tamborlane WV, During MJ. Effect of caffeine on the recognition of and responses to hypoglycemia in humans. Annals Of Internal Medicine 1993, 119: 799-804. PMID: 8379601, DOI: 10.7326/0003-4819-119-8-199310150-00005.Peer-Reviewed Original ResearchConceptsGlucose levelsHypoglycemic symptomsCaffeine consumptionCounter-regulatory hormone levelsHyperinsulinemic glucose clamp techniqueMiddle cerebral artery velocityLarge carbohydrate loadCerebral artery velocityAcute caffeine ingestionClinical Research CenterLevels of norepinephrineAwareness of hypoglycemiaCerebral blood flowDouble-blind designGlucose clamp techniqueLate postprandial periodPlasma glucose levelsLevels of epinephrineBrain glucose useCaffeine-free colaEffects of caffeineAcute ingestionSympathoadrenal activationArtery velocityPlasma glucose
1992
Impaired stimulation of gluconeogenesis during prolonged hypoglycemia in intensively treated insulin-dependent diabetic subjects
Caprio S, Napoli R, Saccà L, Tamborlane WV, Sherwin RS. Impaired stimulation of gluconeogenesis during prolonged hypoglycemia in intensively treated insulin-dependent diabetic subjects. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 1076-1080. PMID: 1400874, DOI: 10.1210/jcem.75.4.1400874.Peer-Reviewed Original ResearchConceptsType I diabetic subjectsHepatic glucose productionDiabetic subjectsGlucose productionControl subjectsInsulin-dependent diabetic subjectsDefective glucose counterregulationFailure of gluconeogenesisLow-dose infusionInsulin-induced hypoglycemiaInsulin-dependent diabetesNormal control subjectsGlucagon responseGlucose counterregulationIDDM patientsIDDM subjectsDose infusionEpinephrine releaseInsulin levelsPlasma glucoseImpaired stimulationConversion of alanineNormal subjectsCompensatory stimulationHepatic response
1983
Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man
Sherwin RS, Schulman GA, Hendler R, Walesky M, Belous A, Tamborlane W. Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man. Diabetologia 1983, 24: 155-161. PMID: 6341144, DOI: 10.1007/bf00250154.Peer-Reviewed Original ResearchConceptsGrowth hormone excessNon-esterified fatty acidsGrowth hormoneHormone excessHigher plasma insulin concentrationsOral glucose toleranceInsulin antagonistic effectsGrowth hormone infusionHigher insulin levelsInfusion of cortisolPlasma insulin concentrationOral glucoseGlucose intoleranceGlucose toleranceSomatomedin concentrationsInsulin levelsFatty acidsHormone infusionPlasma glucoseHyperglycaemic responseInsulin concentrationsNormal suppressionGlucose curveGlucose levelsNormal subjects
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints